These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy. Relizani K; Goyenvalle A Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663 [TBL] [Abstract][Full Text] [Related]
7. Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy. Jirka SMG; 't Hoen PAC; Diaz Parillas V; Tanganyika-de Winter CL; Verheul RC; Aguilera B; de Visser PC; Aartsma-Rus AM Mol Ther; 2018 Jan; 26(1):132-147. PubMed ID: 29103911 [TBL] [Abstract][Full Text] [Related]
8. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion. Maruyama R; Yokota T Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536 [TBL] [Abstract][Full Text] [Related]
9. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results. van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725 [TBL] [Abstract][Full Text] [Related]
10. Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. Kemaladewi DU; Hoogaars WM; van Heiningen SH; Terlouw S; de Gorter DJ; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; ten Dijke P; 't Hoen PA BMC Med Genomics; 2011 Apr; 4():36. PubMed ID: 21507246 [TBL] [Abstract][Full Text] [Related]
11. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy. Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079 [TBL] [Abstract][Full Text] [Related]
12. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108 [TBL] [Abstract][Full Text] [Related]
13. Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy. Miskew Nichols B; Aoki Y; Kuraoka M; Lee JJ; Takeda S; Yokota T J Vis Exp; 2016 May; (111):. PubMed ID: 27285612 [TBL] [Abstract][Full Text] [Related]
14. Challenges of Assessing Exon 53 Skipping of the Human Engelbeen S; O'Reilly D; Van De Vijver D; Verhaart I; van Putten M; Hariharan V; Hassler M; Khvorova A; Damha MJ; Aartsma-Rus A Nucleic Acid Ther; 2023 Dec; 33(6):348-360. PubMed ID: 38010230 [TBL] [Abstract][Full Text] [Related]
15. Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy. Verhaart IE; Heemskerk H; Karnaoukh TG; Kolfschoten IG; Vroon A; van Ommen GJ; van Deutekom JC; Aartsma-Rus A Hum Gene Ther; 2012 Mar; 23(3):262-73. PubMed ID: 22017442 [TBL] [Abstract][Full Text] [Related]
16. Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy. Yokota T; Hoffman E; Takeda S Methods Mol Biol; 2011; 709():299-312. PubMed ID: 21194037 [TBL] [Abstract][Full Text] [Related]
17. The Pharmacokinetics of 2'- Bosgra S; Sipkens J; de Kimpe S; den Besten C; Datson N; van Deutekom J Nucleic Acid Ther; 2019 Dec; 29(6):305-322. PubMed ID: 31429628 [TBL] [Abstract][Full Text] [Related]
18. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. Hanson B; Wood MJA; Roberts TC RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516 [TBL] [Abstract][Full Text] [Related]
19. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient. Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540 [TBL] [Abstract][Full Text] [Related]